

HCV Directly Acting Antivirals & RBV

Charts revised June 2022. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with columns for drug classes (Anaesthetics & Muscle Relaxants, Analgesics, Anthelmintics, Antiarrhythmics, Antibacterials) and drug classes (Antibacterials, Anticoagulant, Antiplatelet & Fibrinolytic, Anticonvulsants). Rows list various drugs with colored symbols indicating interactions.

Table with columns for drug classes (Antibacterials, Anticoagulant, Antiplatelet & Fibrinolytic, Anticonvulsants) and drug classes (Antibacterials, Anticoagulant, Antiplatelet & Fibrinolytic, Anticonvulsants). Rows list various drugs with colored symbols indicating interactions.

For personal use only. Not for distribution.

Key to symbols

Table with 2 columns: Symbol (red dot, orange square, yellow triangle, green diamond) and Description (These drugs should not be coadministered, Potential clinically significant interaction that is likely to require additional monitoring, Potential interaction likely to be of weak intensity, No clinically significant interaction expected).

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice.

HCV Directly Acting Antivirals & RBV

Charts revised June 2022. Full information available at www.hep-druginteractions.org

Page 4 of 6

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Contraceptives and Hormone Replacements (cont)											
Medroxyprogesterone (depot)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone/conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norelgestromin/ethinylestradiol (patch)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone) (depot injection)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone) (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestimate/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel/conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents											
Sildenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gastrointestinal Agents											
Aluminium hydroxide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alverine citrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aprepitant	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cisapride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Droperidol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linaclotide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macrogol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimebutine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
HCC Therapies											
Lenvatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pembrolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Regorafenib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sorafenib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis B Drugs											
Adefovir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2b	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis C Drugs (Direct Acting Antivirals)											
Daclatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elbasvir/Grazoprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
OBV/PTV/r	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
OBV/PTV/r + DSV	◆	◆	◆	◆	n/a	◆	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simeprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis D Entry Inhibitors											
Bulevirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Herbals/Supplements/Vitamins											
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (<i>U. tomentosa</i>)	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginger (<i>Z. officinale</i>)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goldenseal (<i>H. canadensis</i>)	■	■	■	◆	■	■	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Green tea (<i>C. sinensis</i>)	▲	▲	▲	◆	▲	▲	▲	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Kava kava	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Serenoa repens	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆
St John's wort	●	●	●	●	●	●	●	●	●	●	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
HIV Drugs											
<i>Entry/Integrase Inhibitors</i>											
Albuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	▲	◆	■	■	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	■	●	◆	◆	●	●	●	◆	◆	◆	◆
Elvitegravir/cobi/FTC/TDF	■	●	◆	◆	●	●	●	◆	◆	◆	◆
Enfuvirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	●	▲	▲	▲	▲	▲	◆	◆	◆	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Dapivirine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Efavirenz	■	●	●	◆	●	●	●	◆	◆	◆	◆
Etravirine	■	●	●	◆	●	●	●	◆	◆	◆	◆
Nevirapine	■	●	●	◆	●	●	●	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rilpivirine/dolutegravir	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	◆
<i>NRTIs</i>											
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Didanosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Emtricitabine + TAF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Emtricitabine + TDF	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	■
Stavudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
Tenofovir-DF (TDF)	◆	◆	◆	◆	■	■	◆	◆	◆	◆	■
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	●
<i>Protease Inhibitors</i>											
Atazanavir alone	◆	●	●	◆	■	■	●	◆	◆	◆	■
Atazanavir/cobicistat	■	●	●	◆	●	●	●	◆	◆	◆	■
Atazanavir + ritonavir	■	●	●	◆	●	●	●	◆	◆	◆	■
Darunavir/cobicistat	◆	●	●	◆	●	●	●	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	●	●	◆	●	●	●	◆	◆	◆	◆
Darunavir + ritonavir	◆	●	●	◆	■	■	●	◆	◆	◆	◆
Fosamprenavir	■	●	●	◆	■	■	●	◆	◆	◆	◆
Indinavir	■	●	●	◆	●	●	●	◆	◆	◆	◆
Lopinavir	◆	●	●	◆	●	●	●	◆	◆	◆	◆
Ritonavir	■	●	●	◆	●	●	●	◆	◆	◆	■
Tipranavir	■	●	●	◆	●	●	●	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised June 2022. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Hypertension/Heart Failure Agents											
Acebutolol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bosentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Irbesartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isradipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ivabradine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olmесartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rilmenidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sildenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Torasemide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valsartan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Illicit/Recreational											
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mephedrone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Immunosuppressants											
Adalimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alemtuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anakinra	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baricitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclosporin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eculizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pirfenidone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sirolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tacrolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lipid Lowering Agents											
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rosuvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simvastatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

HCV Directly Acting Antivirals & RBV

Charts revised June 2022. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; ELB/GZR, Elbasvir/Grazoprevir; G/P, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs											
Acamprosate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Allopurinol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	▲	▲	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bamlnivimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	◆	▲	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Casirivimab/imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colestyramine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Conivaptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Convalescent plasma (COVID-19)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamfetamine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Donepezil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eliglustat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ermicizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Goserelin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Interferon beta	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Levothyroxine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Lofexidine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Lumacaftor/lvacaftor	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Penicillamine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

	DCV	ELB/GZR	G/P	LED/SOF	OBV/PTV/r	OBV/PTV/r+DSV	SMV	SOF	SOF/VEL	SOF/VEL/VOX	RBV
Other Drugs Continued											
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	▲	◆	▲	▲	▲	▲	▲	▲	▲	▲	▲
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxytocics											
Ergometrine (ergonovine)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mifepristone	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents											
Benzotropine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ropinrole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
PBC Agents											
Obeticholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids											
Beclometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Urological Agents											
Alfuzosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.